Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H24N2O4S2 |
Molecular Weight | 408.535 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CCC[C@H](N1C(=O)[C@H](CCS2)NC(=O)[C@@H](S)CC3=CC=CC=C3)C(O)=O
InChI
InChIKey=LVRLSYPNFFBYCZ-VGWMRTNUSA-N
InChI=1S/C19H24N2O4S2/c22-17(15(26)11-12-5-2-1-3-6-12)20-13-9-10-27-16-8-4-7-14(19(24)25)21(16)18(13)23/h1-3,5-6,13-16,26H,4,7-11H2,(H,20,22)(H,24,25)/t13-,14-,15-,16-/m0/s1
Molecular Formula | C19H24N2O4S2 |
Molecular Weight | 408.535 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.medscape.com/viewarticle/443224Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00886
Sources: http://www.medscape.com/viewarticle/443224
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00886
Omapatrilat is an antihypertensive agent that inhibits both neprilysin (neutral endopeptidase, NEP) and angiotensin-converting enzyme (ACE). The drug was developed for possible use in heart failure and hypertension, but was not approved by the FDA due to angioedema safety concerns.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25953200
Curator's Comment: Known to be CNS non-penetrant in rats. Human data not available.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11890357
Curator's Comment: # Bristol-Myers Squibb
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P12821 Gene ID: 1636.0 Gene Symbol: ACE Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10856268 |
0.06 nM [Ki] | ||
Target ID: CHEMBL1944 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19899765 |
9.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats. | 2005 Sep 20 |
|
Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. | 2008 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16086927
In phase III trial, omapatrilat was administered at dose 40 mg every day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10856268
Inhibition studies of recombinant angiotensin-converting enzyme (ACE) and were performed with the use of Ang I, HHL, and the new synthetic peptide AcSDAcKP as substrates. The inhibitory potency of omapatrilat and toward recombinant wild-type ACE was determined by establishing dose dependent inhibition curves at equilibrium. Inhibition of Ang I, HHL, and AcSDAcKP hydrolysis was determined with the use of 0.1 nmol/L, 0.1 nmol/L, and 0.4 nmol/L of wild-type ACE respectively. After preincubation with 0.05 to 2.5 nmol/L of inhibitor at 37°C for 1 hour, reactions were initiated by substrate addition at 2 different concentrations (0.53Km and 33Km) and performed for 5, 10, 30, and 60 minutes. The rate of hydrolysis of all the substrates used was quantified by high-performance liquid chromatography.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:54:11 GMT 2023
by
admin
on
Fri Dec 15 15:54:11 GMT 2023
|
Record UNII |
36NLI90E7T
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C247
Created by
admin on Fri Dec 15 15:54:11 GMT 2023 , Edited by admin on Fri Dec 15 15:54:11 GMT 2023
|
||
|
NCI_THESAURUS |
C783
Created by
admin on Fri Dec 15 15:54:11 GMT 2023 , Edited by admin on Fri Dec 15 15:54:11 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
167305-00-2
Created by
admin on Fri Dec 15 15:54:11 GMT 2023 , Edited by admin on Fri Dec 15 15:54:11 GMT 2023
|
PRIMARY | |||
|
CHEMBL289556
Created by
admin on Fri Dec 15 15:54:11 GMT 2023 , Edited by admin on Fri Dec 15 15:54:11 GMT 2023
|
PRIMARY | |||
|
DTXSID80168273
Created by
admin on Fri Dec 15 15:54:11 GMT 2023 , Edited by admin on Fri Dec 15 15:54:11 GMT 2023
|
PRIMARY | |||
|
Omapatrilat
Created by
admin on Fri Dec 15 15:54:11 GMT 2023 , Edited by admin on Fri Dec 15 15:54:11 GMT 2023
|
PRIMARY | |||
|
m8207
Created by
admin on Fri Dec 15 15:54:11 GMT 2023 , Edited by admin on Fri Dec 15 15:54:11 GMT 2023
|
PRIMARY | Merck Index | ||
|
36NLI90E7T
Created by
admin on Fri Dec 15 15:54:11 GMT 2023 , Edited by admin on Fri Dec 15 15:54:11 GMT 2023
|
PRIMARY | |||
|
DB00886
Created by
admin on Fri Dec 15 15:54:11 GMT 2023 , Edited by admin on Fri Dec 15 15:54:11 GMT 2023
|
PRIMARY | |||
|
7714
Created by
admin on Fri Dec 15 15:54:11 GMT 2023 , Edited by admin on Fri Dec 15 15:54:11 GMT 2023
|
PRIMARY | |||
|
C1782
Created by
admin on Fri Dec 15 15:54:11 GMT 2023 , Edited by admin on Fri Dec 15 15:54:11 GMT 2023
|
PRIMARY | |||
|
JJ-01
Created by
admin on Fri Dec 15 15:54:11 GMT 2023 , Edited by admin on Fri Dec 15 15:54:11 GMT 2023
|
PRIMARY | |||
|
SUB12450MIG
Created by
admin on Fri Dec 15 15:54:11 GMT 2023 , Edited by admin on Fri Dec 15 15:54:11 GMT 2023
|
PRIMARY | |||
|
656629
Created by
admin on Fri Dec 15 15:54:11 GMT 2023 , Edited by admin on Fri Dec 15 15:54:11 GMT 2023
|
PRIMARY | |||
|
C106266
Created by
admin on Fri Dec 15 15:54:11 GMT 2023 , Edited by admin on Fri Dec 15 15:54:11 GMT 2023
|
PRIMARY | |||
|
100000078754
Created by
admin on Fri Dec 15 15:54:11 GMT 2023 , Edited by admin on Fri Dec 15 15:54:11 GMT 2023
|
PRIMARY | |||
|
1989
Created by
admin on Fri Dec 15 15:54:11 GMT 2023 , Edited by admin on Fri Dec 15 15:54:11 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
PLASMA
|
||
|
METABOLITE -> PARENT |
PLASMA
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |